10x Genomics (TXG) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$616.9M

Revenue (quarter)

$151.0M

Revenue growth (year over year)

−12.65%

Gross profit (trailing twelve months)

$432.0M

Gross margin

70.03%

Net income (trailing twelve months)

−$75.1M

Net income (quarter)

−$17.9M

Net income growth (year over year)

−151.92%

Net margin

−12.18%

Return on equity

−9.40%

EPS (trailing twelve months)

−$0.59

Book value per share

$6.34

P/E (trailing twelve months)

—

Price to book

11.33

Debt to assets

19.86%

Payout ratio

—

Dividend yield

—

Company profile

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

• Is 10x Genomics (TXG) profitable?

  No. 10x Genomics reported a net loss of $75.1M over the trailing twelve months.

• How much revenue does 10x Genomics (TXG) make?

  10x Genomics generated $616.9M in revenue over the trailing twelve months, down 12.65% year over year.

• How do I buy stock in 10x Genomics (TXG)?

  TXG trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.